Lixte Biotechnology Holdings Stock Revenue
| LIXT Stock | USD 2.23 0.06 2.76% |
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
| Last Reported | Projected for Next Year |
Lixte | Revenue |
Lixte Biotechnology Holdings Company Revenue Analysis
Lixte Biotechnology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lixte Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Revenue. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Lixte Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Lixte Biotechnology Holdings reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Lixte Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in revenue category among its peers.
Lixte Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lixte Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lixte Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Lixte Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Lixte Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lixte Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotechnology's value.| Shares | Hightower Advisors, Llc | 2024-09-30 | 99.4 K | Fny Investment Advisers, Llc | 2024-06-30 | 50.3 K | Ethos Financial Group Llc | 2024-09-30 | 24.8 K | Geode Capital Management, Llc | 2024-09-30 | 17.2 K | Tower Research Capital Llc | 2024-09-30 | 2.1 K | Ubs Group Ag | 2024-09-30 | 367 | Bank Of America Corp | 2024-06-30 | 309 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 |
Lixte Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 6.88 M | ||||
| Shares Outstanding | 2.25 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 9.64 % | ||||
| Number Of Shares Shorted | 189.13 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 12.00 X | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 313.86 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Short Ratio | 0.31 X | ||||
| Earnings Per Share | (1.73) X | ||||
| Beta | -0.17 | ||||
| Market Capitalization | 5.02 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
| Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.